The $290M Cancer Biotech With Phase 3 “Proof”: Candel (CADL)’s Viral Immunotherapy Isn’t Just a Science Fair Anymore
We recently published our article Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next. This piece…
Top 10 Cancer Biotech Small-Caps That Could Shock the Market Next
In this article, we will take a look at the Top 10 Cancer Biotech Small-Caps That Could Shock…
The “In Situ” Miracle: Why Candel Therapeutics (CADL) Just Doubled Life Expectancy!
Founded in 2016 by a group of visionary scientists and industry veterans from the Dana-Farber Cancer Institute and…
Candel Therapeutics (CADL) Boosts Cash to $217M, Prepares for 2026 Prostate Cancer Launch
Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company pioneering the next generation of cancer immunotherapies by harnessing…
Candel Therapeutics (CADL) Poised for 272% Upside
Candel Therapeutics, Inc. (NASDAQ:CADL) is a clinical-stage biotechnology company pioneering viral immunotherapies that aim to turn a patient’s…
Is Candel Therapeutics (CADL) the Next Big Cancer Stock? Analysts Say Yes—And It’s Still Cheap
Candel Therapeutics Inc. (NASDAQ:CADL) is a Massachusetts-based clinical-stage immuno-oncology company that traces its roots to pioneering gene-therapy research…
Candel Therapeutics (CADL) is a Rising Star in Cancer Immunotherapy
Candel Therapeutics Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company pioneering a new class of cancer immunotherapies that leverage…